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ABSTRACT

Murine lymphocyte activating factor

(LAF), a leukocyte

product which enhances DNA synthesis in thymocytes,
studied.
of Eh

In vivo stimulation with intraperitoneal

coli lipopolysaccharide

(LPS) was employed,

was
injections

and spleen

and peritoneal cells were found to produce LAF within three
hours.

The kinetics and optimal conditions for production

of peritoneal and splenic LAF were explored.

Enhancement of

peritoneal LAF production after LPS challenge was attained
by pre-treating the animals with the methanol extraction
residue of the tubercle bacillus

(MER),

The synergistic effect of murine LAF with several mito¬
gens,

including phytohemagglutinin-P,

Concanavalin A and the

supernatant fraction from human peripheral blood leukocytes
was demonstrated.

It was also shown that dialysis of crude

LAF preparations apparently removed an inhibitory substance.
Preliminary data suggested that the molecular weight of
murine LAF is 55*000 daltons and the

isoelectric point is 5»°.

Both these values are considerably different from those
previously reported for human leukocyte LAF,

but are com¬

parable to values determined for a murine cell line.

»
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LITERATURE REVIEW
The Role of Macrophages in the Immune Response
Macrophages or adherent mononuclear phagocytes have an
important accessory role in cell-mediated immunity.

Both the

adherent and non-adherent populations of murine spleen cells
are required to produce antibody to sheep red blood cells.1
Macrophages appear to be responsible for the uptake and
processing of antigens.
highly immunogenic.

p

Antigens bound to macrophages are

Live peritoneal exudate macrophages,

when transferred from an animal with exposure to a specific
antigen to an animal which has not been exposed to that anti1

gen will provoke a specific immune response."®

4

Albumin

bound to live macrophages is approximately one thousand-fold
more immunogenic than a comparable amount of free antigen.The macrophage, however, does not appear capable of
actually producing antibody.

If stimulated macrophages are

transferred into X-irradiated hosts"' or recipients immuno»
logically tolerant to the antigen,^ there will be almost no
antibody production.
The specificity of the immune response resides with the
committed lymphocytes.
many antigens.

7

The macrophages can interact with

However, if a specific clone of lymphocytes In

a population of spleen cells is rendered non-functional by a

.
* ■ ■ f. ''(■:>:
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highly radioactive

antigen, the immune response to that

antigen is lost when the spleen cells are transferred to
O

X-irradiated mice*
The question to be evaluated in this thesis is whether
in a non-specific immune response (mitogenesis of thymocytes
in the absence of antigen) the macrophage from a mouse exposed
to antigen can be replaced by a soluble leukocyte-derived
factor*

As demonstrated below, evidence for the existence of

such a factor has already been presented in the literature*
The object of these studies is to determine the kinetics of
its production in vivo and to partially purify and charac¬
terize the factor*
Soluble Leukocyte-Derived Specific Lymphocyte Stimulators
The earliest evidence that a soluble factor released
by macrophages could be substituted for intact macrophages
in certain immune responses came from systems which tested
the ability of lymphocytes to respond to certain specific
antigens.

9

In 1970 Dutton et al.y demonstrated that adherent

mouse spleen cells restored the responsiveness of non-adherent
spleen cells to sheep erythrocytes*

They also demonstrated

that conditioned medium manufactured by incubated adherent
cells could restore response to this antigen®

Of Interest

was the fact that the supernatant fraction of cultured
macrophages was effective even when the macrophages were not
incubated in the presence of sheep erythrocytes.

However,

since the fetal bovine serum used in the medium contained

»
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antigens which cross reacted with sheep erythrocytes, it was
not possible to determine from these data whether the factor
produced by the macrophages was non-specific®

Bach et al.1Q

studied the response of purified lymphocytes to allogeneic
lymphocytes and demonstrated the need for a soluble macrophage
factor, which he designated CMRF (conditioned medium reconsti¬
tuting factor).

The response was to a specific antigen and

the macrophages were incubated in 20% plasma®

Cross reacti¬

vity could not be ruled out®
A Non-Specific Lymphocyte Activating Factor
Gery, Gershon and Waksman

11

12

were the first to demon¬

strate that a macrophage-derived factor could stimulate
thymus-processed

(T-) lymphocytes in the absence of antigen®

Mouse thymocytes cultured without any stimulant or in the
presence of phytohemagglutinin-P (PHA) incorporated only a
small amount of tritiated thymidine®

However, when as few as

6,000 human peripheral blood leukocytes were added in addition
to PHA, a definite increase in thymidine incorporation
occurred®

When the supernatant , fraction of human leukocyte

cultures incubated with PHA or lipopolysaccharide (LPS) was
added to the thymocyte cultures, it resulted in a greater
than one hundred-fold rise in the incorporation of thymidine
by the thymocytes, both in the presence and absence of PHA.
Syngeneic spleen cells stimulated with PHA, LPS or Goncanavalin A (CON A) also produced supernatant fractions which
13
increased mouse thymocyte DNA synthesis. "■

. •
No specific

A

■'

antigens had to he added to the thymocyte cultures.
Additional experiments by Gery and Waksman1^ revealed
that this factor, which they designated lymphocyte activating
factor (LAF), was produced primarily,
macrophages.

but not exclusively,

by

They designated those cells which were adherent

to plastic and nylon columns as macrophages, although no
morphological data was presented.

The adherent population

of mouse spleen cells produced a conditioned medium with
more activity than that produced by unpurified spleen cells.
The adherent human leukocytes produced more potentiating
factor per cell than the total leukocyte population.

Although

the adherent cell population consists primarily of macrophages,
contamination with other cells cannot be excluded.

It is

possible that the cooperation of other cells is necessary
for the production of LAF.
Experiments by Yoshmaga et al»

14

demonstrated that

peritoneal exudate cells of mice stimulated intraperitoneally
with caseinate or the supernatant fraction derived from peritoneal exudate fluid will induce DNA synthesis in mouse thymo¬
cytes.

The peritoneal exudate cells obtained three hours after

caseinate injection consisted of 93polymorphonuclear leuko¬
cytes and only 2% macrophages.
macrophages and 26% lymphocytes®

At 96 hours there were 73%
Supernatant fractions from

cultures of both the 3-hour and 96-hour exudate cells enhanced
thymocyte DNA synthesis.

The number of macrophages contained

in the 3-hour peritoneal exudate cells
was insufficient,

by itself,

(6.4 x 102 cells/cc)

to produce a supernatant fraction

•

■

iq>.

;

■

-

•

'

6
capable of inducing mitogenesis.

Although adherent cells

definitely appear to produce LAF, other leukocytes,

particu¬

larly polymorphonuclear leukocytes, also appear to produce
this substance..
T-cell cooperation may be an important element in LAF
production,

Gery and Waksman

13

compared the production of

LAF by cultures of mouse spleen cells with cultures of spleen
cells from irradiated mice reconstituted with either syngeneic
bone marrow cells or bone marrow plus thymus cells.

Super¬

natant fractions from the PHA or CON A stimulated cultures
obtained from the animals reconstituted with both thymus and
bone marrow cells produced greater thymocyte response than
the supernatant fractions from the cultures obtained from
animals reconstituted with marrow cells alone.

It would

appear that there is a positive feedback mechanism involved
in LAF production,

in which the production of LAF by adherent

cells is enhanced by T cells.

15

This was confirmed by Unanue

et al. ^, who enhanced LAF production by peritoneal exudate
cells from Listeria infected mice by adding in vitro the
activated T-lymphocytes from the peritoneum of similarly
infected animals.
LAF is produced in vitro by cells from many species,
including guinea pig macrophages,
and lung macrophages,

dog leukocytes and spleen

as well as monkey leukocytes.

However,

under very similar conditions thymocyte stimulation was not
produced by conditioned medium from cultures of L1210,

L5178Y,

•-'X.o

£

X

,
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vero,

BHK, HeLa or L-fibroblasts,

despite the addition of LPS

to the cell cultures.1^’
LAF has been produced in vivo after both acute and pro¬
longed stimulation.

Supernatant fractions obtained from

1-hour cultures of peritoneal exudate cells harvested 3 and

96 hours after casein injection displayed LAF activity.

Cell-

free peritoneal exudate harvested at 3 and, 9 hours also
enhanced thymocyte mitogenesis.

14

Mitchell et al.

found LAF

activity in the conditioned medium of 24 hour cultures of
spleen cells from mice given the BCG strain of tubercle bacil¬
lus intravenously 7 to 14 days previously.1^

Gery et al.

demonstrated enhanced production of LAF by peritoneal cells
in animals which 7 days previously had received an intraperitoneal injection of the methanol extraction residue of BCG.
LAF production can be stimulated by a variety of sub¬
stances.

Supernatant fractions with LAF activity have been

obtained from human leukocytes incubated for 24 hours with
LPS.

Mitogens such as PHA and CON A promoted the release of

LAF,1^ as did cyclic GMP.21

Irradiation in vivo increased

the production of LAF by peritoneal exudate cells.22
investigators1^*

Other

have added latex particles, antibody-

coated red blood cells.

Listeria organisms and beryllium salt

in vitro to peritoneal exudate cell cultures and found that
these substances increase the production of a factor capable
of interacting with macrophages and producing enzymatic and
morphological changes.

However,

Unanue's group did not find

vo b C D

8
a direct relationship between morphologic changes in the macrophage and the secretion of lymphostimulatory material*
et al®

ok

Gery

found that LAF production by peritoneal cells

activated either in vitro or in vivo did not necessarily
correlate with the secretion of lysosomal enzymes.
There is evidence for the existence of macrophage products
which both stimulate and inhibit lymphocytes*2^

It is

important to note that several authors have found a soluble
macrophage product which inhibits thymidine incorporation by
lymphocytes stimulated with PHA.2^"2^

Opitz and his group^0

studied this suppressor and found that it merely reduced
thymidine incorporation without inhibiting DNA synthesis as
measured by cell proliferation*

Inhibition was temporary and

ceased when the substance was washed out.
factor was dialyzable and heat stable®

The suppressing

The most attractive

explanation was that the macrophages were releasing thymidine,
which diluted the radioactively labelled thymidine.

Macro¬

phages cultured with T-lymphocytes present on the opposite side
of a separation chamber did not produce the inhibitor of
thymidine uptake, and Opitz et al« postulated that macrophages
phagocytize and degrade dead lymphocytes and subsequently
release degradation products, including thymidine,

into the

medium.
LAF obtained from human leukocytes and mouse peritoneal
cell cultures stimulated with endotoxin has been purified and
characterized•31-3^

it was non-dialyzable, heat labile.

*

,.

*•
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and it could be precipitated by ammonium sulfate.

Sephadex

chromatography localized activity in fractions containing
molecules ranging in weight from 5,000 to 25,000 dal.tons
with a peak of activity at 15*000.^2

Calderon et al»

described a molecule with similar stimulatory activity and
a molecular weight of between 15*000 and 21,000 daltons.

The

molecule was not sensitive to diisopropylfluorophosphate
treatment, but was sensitive to chymotrypsin and pepsin.

The

"’enhancing factor" discussed by Nakamura et al. ^ was prepared
from polymorphonuclear leukocytes in the mouse peritoneal
exudate.

It was also capable of potentiating DNA synthesis

by syngeneic thymocytes stimulated with PHA.

This factor had

a molecular weight of 19*000, was non-dialyzable, heat labile
and stable in solutions with a pH ranging between 3 and 9«
In addition, the LAF activity was associated with a proteo¬
lytic activity on 3H-aeetyi hemoglobin.

Both the thymocyte

stimulating effect and the proteolytic effect were abolished
by Trasylol, a protease inhibitor.

Since two leukocyte

products could elute in the same Sephadex fraction, these
findings do not prove that the molecules are identical.
Lachman et aJU

35

presented evidence that LAF from a murine

peritoneal cell line P388-DI has a much higher molecular
weight (80,000 daltons).
Enhancement of Immune Responsiveness and Its Possible Role
in Tumor Immunotherapy
Over one hundred years ago, Busch, a Viennese physician.

i

*

-

,■

*
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noted that some malignant tumors appeared to regress coinci¬
dentally with the occurrence of erysipelas®-'''

Fifty years

ago Coley treated cancer patients with bacterial culture
fluids (Coley’s toxin), which contained endotoxin among
other cellular products®
in some of his patients®3?

He achieved striking tumor regression
Although the mechanism by which

these agents might have acted is unclear, the results provided
impetus for scientists to study immune enhancement as a means
of cancer therapy®
BCG Immunotherapy
Recently a modified strain of the tubercle bacillus,
(Bacillus Calmette-Guerin or BCG) has been investigated in
humans as an adjuvant to surgery and conventional cancer
chemotherapy®38* 39
response

Many investigators have demonstrated a

to BCG in animal tumors, particularly those induced

by carcinogens and a mouse lymphoid leukemia line®^®"^4"
The mechanism of action of BCG, endotoxin and other
immunetherapeutic agents is not completely understood, but
clues have been emerging®

Mitchell et al®~

reported

increased cell-mediated immunity in mice inoculated with
BCG®

Spleen cells from these animals had increased capa¬

city to lyse tumor cells®

Also the spleen cells from BCG-

treated animals produced more of the lymphocyte activating
factor, as demonstrated by the ability of supernatant fluid
from the splenocytes to increase syngeneic thymocyte DNA
incorporation®

The adherent spleen cells from the treated

*

f. ' *

.

11
animals produced 3 to 3s times the LAF activity of the normal
mouse adherent spleen cells®
The human melanoma appears to be an ideal tumor for
immunetherapy, since it is capable of causing an immune
response®

Nagel et al.^5 observed specifically sensitized

lymphocytes in an individual who had recently undergone
surgery for malignant melanoma®

Bodurtha et al.

46

found a

complement dependent cytotoxic antibody to autochthonous
tumor cells in the serum of nine of ten patients with local¬
ized or regionalized melanoma and in only one of eleven
patients with disseminated metastases®
Endotoxin, the Immune Response and Tumor Immunotherapy
Endotoxin or lipopolysaccharide (LPS) from gram negative
bacteria has been utilized to stimulate an immune response
and render macrophages cytotoxic®

In certain situations

endotoxin has been used successfully to cause tumor necrosis
and increase mouse resistance to tumor®
The immune response to LPS appears to involve primarily
B-lymphocytes and macrophages®^?

Both athymic (nude) mice

and their normal littermates respond in the same primary and
secondary fashion to LPS.

This was not the case for the

response to equine erythrocytes®

The immune response to this

agent was severely impaired in the athymic mice®

Both an

antibody response and a specific plaque forming cell response
can be demonstrated after an intraperitoneal or Intravenous
injection of LPS.

A primary effect can be demonstrated after

*
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the injection of as little as 10“3 Ug 0f LP8,
Alexander and Evans

48

demonstrated that endotoxin as well

as double-stranded RNA could "activate" mouse macrophages and
provide them with the capability of killing mouse lymphoma
cells.

A macrophage preparation obtained from peritoneal

cells was unable to inhibit the growth of lymphoma cells
unless the macrophages had been exposed to endotoxin for at
least thirty minutes.

These "activated" macrophages differed

from "stimulated" peritoneal macrophages, which resulted from
intraperitoneal injection of BCG or thioglycollate•

Stimulated

macrophages contained an increased number of lysosomes but
were incapable of inhibiting the growth of lymphoma cells.
Currie and Basham^ reported that cellular apposition was
not a prerequisite for macrophage toxicity and that a stable
supernatant product was capable of lysing tumor cells.
Several derivatives of endotoxin appear to have anti¬
tumor activity.

A group in Japan^0? 51 found a protein

fraction of endotoxin from Pseudomonas aeruginosa was capable
of inhibiting the growth of ascites sarcoma 180, while the
/

intact LPS from these bacteria was ineffective.

Nowotny,

Golub and Key^2 demonstrated that the complete endotoxin, the
non-toxic endotoxoid (prepared from endotoxin by deacylation
with potassium methylate) and endotoxin glycolipids all were
capable of producing hemorrhagic necrosis in tumors.
The literature is replete with demonstrations of the
effectiveness of endotoxin in inhibiting tumor growth.

■

.
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Several mechanisms appear to be operational:
necrosis,

hemorrhagic

enhancement of tumor antigenicity by endotoxin

coating of tumor cells, and generalized enhancement of the
immune recognition system*
Parr, Wheeler and Alexander^ studied several variables
related to hemorrhagic necrosis.

Treatment with endotoxin

or double-stranded RNA was effective against subcutaneous or
intradermal tumors,
tumors.

but had no effect on intraperitoneal

Unless the tumor was "established"

for seven days),

(had been implanted

endotoxin was not effective.

The authors

demonstrated that several host factors contributed to tumor
regression.

Vascular hemorrhage had

be blocked by heparin.

to occur and this could

Immunosuppression by whole body

irradiation or anti-lymphocyte serum also interfered with tumor
regression,

despite the fact that hemorrhage still occurred.

Tumor antigenicity (the number of cells rejected after immuni¬
zation with irradiated tumor cells)

correlated with the magni¬

tude of anti-tumor activity of systemically introduced endotoxin

,^

against specific tumors

Based on these results,

it would

appear that both vascular damage, which permits the endotoxin
and various cellular elements and products to gain access to
the tumor, and activation of an immune response are required,
A serum factor has been isolated which appears to mediate
hemorrhagic necrosis and mimics endotoxin in this effect.
It can be produced by administering endotoxin intravenously to
mice which had received BCG two weeks previously.

The tumor

*

,

,
_
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necrosis factor is not residual endotoxin.

This glycoprotein

has a molecular weight of 150,000 dal tons and migrates with
the c*-globulins.

The BCG appears to "activate” macrophages

and produces an increase in lysosomes.

The macrophages

apparently become extremely sensitive to endotoxin, which
releases the macrophage contents by disruption. ^-)9
Two groups produced tumor rejection by administering
tumor cells or modified tumor cells in the presence of endoI'ty

toxin®"

rQ

*

The endotoxin had no apparent direct toxic

effect on the tumor cells,

but rather appeared to cause a

localised stimulation of host resistance,

perhaps by coating

the tumor cells and making them more immunogenic.

The animals

were able to resist a lethal dose of tumor cells administered
after the simultaneous administration of tumor and endotoxin®
This response was not obtained when only modified tumor cells
or only endotoxin was given prior to the lethal dose challenge
Bober and her
small amounts

group-59

found intraperitoneal injection of

(0.1 to 0.5 ug) of endotoxin protected mice

against a challenge of a mineral oil induced plasma cell
tumor.

Endotoxin treatment before and after tumor injection

provided the best protection and this effect was seen with
both intraperitoneally and subcutaneously injected tumor.
Mice injected with the TA3-Ha mouse ascites cell line
were able to suppress tumor growth when immunized with a
small amount (10 ug) of endotoxin prior to tumor challenge•*
The TA3-Ha tumor line is one which lost strain specificity but

6i

'
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which retained major histocompatibility antigens*

Sensitiza-

tion of allogeneic mice with skin grafts from strain A mice
in which the tumor originated caused the recipient mice to
become relatively tumor resistant®

Stimulation of the host

immune system by the intraperitoneal injection of 10 ug of
endotoxin 3 to 0 days prior to tumor inoculation was
sufficient to enable the host to destroy a lethal tumor dose®
The endotoxin did not have a direct cytotoxic effect on tumor
cells®

Protection against tumor could be adoptively trans¬

ferred by normal spleen cells exposed in vivo and in vitro
to endotoxin®

These experiments support the use of generalized

enhancement of the immune response and host resistance as a
means of controlling tumor growth and suggest that this
approach should be especially successful against tumors with
a high degree of antigenicity®

J,

materials and methods

Animals
B6D2F1 mice obtained from Cumberland Farms were used for
all experiments unless otherwise noted®

Upon arrival the

animals weighed 18 to 20 grams and were approximately 6
weeks old®

The mice were given a one week course of strepto¬

mycin in the drinking water (40 ug/cc) and completed treat¬
ment at least one week prior to the experiments.
were fed Purina Lab Chow®
mice were 3s
mice

The animals

At the time of the experiments the

to 5 months of age and weighed 30+3 grams®

GDI

(Cumberland Farms, age 18 weeks, average weight 45 grams)

and C3H mice

(Charles River Laboratories, age 1? weeks,

average weight 2? grams) were used in one experiment®
Thymus cells for the lymphocyte activating factor (LAF)
assay (see below) were obtained from GDI mice age 8 to 10
weeks®

Reagents
Lipopolysaccharide B from Escherishia coli strain 055*B5
(LPS, Difco Laboratories, Detroit, MI, Lot 611788) was used®
Suspensions were prepared in 0.9% sterile saline, and the
required dosage was contained In 0®2 cc of saline®
The methanol extraction residue of Bacillus Calmette-Guerin

. •' >
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(Phipps strain) or MER was a gift of the National Cancer
Institute®

The preparation used.

Lot BV 73-240,

MER in a concentration of 2 mg/cc,
sodium carboxymethyl cellulose
(0.004 cc/cc)

in sterile wafer.

mice received 0®5 cc

contained

sodium chloride

(9 mg/cc),

(5 mg/cc) and polysorbate 80
In some experiments the

(1 mg) of MER intraperitoneally 5 days

prior to receiving an intraperitoneal injection of 50 ug of
LPS,
All injections were done intraparitoneally using a #26
gauge disposable needle and a 1 cc or 5 cc Plasti-pak syringe
(Becton-Dickenson,

Rutherford,

NJ).

Recovery of %-LPS from Peritoneal Washings

Tritiated LPS was prepared by New England Nuclear
(0.166 mC/mgj,

special order #84l-269“29?7) by exposing 190 mg

of EH coli LPS to 3 curies of tritium at 24°c for 2 weeks
and lypholyzing the product 4 times.

Twelve mice received

an intraperitoneal injection of a mixture containing 10 ug
of tritiated LPS and 90 ug of non-radioactive LPS in 0.2 cc
of normal saline.

Immediately following Injection, 6 animals

were sacrificed and 6 animals were killed 4 hours after the
injection.

Three cc of Minimal Essential Medium with Earle's

salts (MEM, Grand Island Biological Company, Grand Island,
NY) supplemented with glutamine
U/liter),

(2 mM), penicillin

(1000

streptomycin (1000 ug/liter) and 0.05 M HEPES

(Calbiochem,

La Jolla,

CA) at pH 7*4 was injected intraperi¬

toneally with a #26 gauge needle and the peritoneum was

.

V

'
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gently agitated®

(Note;

Throughout the remainder of this

report MEM will refer to the supplemented MEM just described.)
Two cc

(+10°/o) of fluid was aspirated back and centrifuged at

500 g for 15 minutes®

The supernatant fraction was decanted,

added to 2 cc of scintillation fluid

(described below), and

counted in a liquid scintillation counter for 1 minute.

Production of Lymphocyte Activating Factor

(LAF)

Peritoneal washings that contained lymphocyte activating
factor (LAF) were prepared by injecting B6D2F1,

GDI and G3H

mice intraperitoneally with various dosages of lipopolysaccharide

(LPS).

At a specified time period after the LPS

injection the mice were sacrificed by cervical dislocation®
The skin and abdominal muscles were incised to expose the
peritoneum.

Three cc of MEM was injected intraperitoneally

and the peritoneum was gently agitated.

Approximately 2 cc

of fluid was aspirated back using the same needle®

The

fluid was centrifuged at 5GQ g for 10 minutes and the super¬
natant fraction was sterile filtered through a 45 n Millipore
filter (Swinnex 0.45

13 mmj Millipore Corporation).

Samples were either assayed immediately or frozen at -4°C
following the addition of human serum
gical Company,

(Grand Island Biolo¬

Lot 4030068) equivalent to 5$ of sample

volume®
Splenic LAF was piroduced by injecting various strains
of mice with LPS in the manner described above®
were sacrificed and the spleens were removed.

The animals
The spleens

»
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were placed in 5 cc of MEM and homogenized individually by
hand with a Potter Elvejehm homogenizer with a Teflon pestle
(McAllister Bicknell Co.},

The spleen cells were then cultured

at various concentrations and for various periods of time in
15 x 100 mm plastic Petri dishes
Oxnard,

CA).

(Fsilcon Plastics,

Plates we re incubated at 3?°C with

5%

#1029,
C02-

After 0 to 28 hours the plates were removed from the incubator
and

the suspension was centrifuged at 500 g for 10 min.

The

supernatant fraction was decanted and sterile filtered.

The

filtrate was either assayed immediately or treated with
serum

(5$ v/v) and frozen.
In some experiments various substances were added to

the splenocyte cultures.
plasma

These

included LPS,

human AB+ donor

(Mew York. City Red Cross Blood Bank), and

thymocytes.

isogeneic

The thymocytes were prepared by removing

the thymuses from B6D2F1 mice and homogenizing them in 5 cc
of MEM, as described previously.

The thymocytes were

counted in a hemacytometer and diluted with MEM to a concen7
tration of 1 x 10' cells per cc.

One cc of this suspension
ft

was then added to a suspension containing 5 x 10° splenocytes
per cc.

The final thymocyte concentration was 1 x 10^ cells/cc.

The LAF Assay
The standard LAF assay initially developed by Gery,
Gershon and Waksman^ and modified by Blyden and Handschumacber1®
was used.

Essentially,

this assay measured the ability of a

-

'v
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substance to promote thymidine incorporation in a population
of thymus cells.

Thymuses were removed from 8 to 10 week GDI

mice and homogenized individually in MEM with a Potter Elvejehm
homogenizer with a Teflon pestle®

The thymocytes were pooled

and their concentration determined in a hemacytometer*

The

/■

concentration was adjusted to 5 x 10° cells per cc by dilution
with MEM.

Human serum was added to this suspension to a

final concentration of 5% (v/v), and 2-mereaptoethanol was
added to a final concentration of 0*05 mM.

One cc aliquots

of this suspension were pipetted into the cylindrical wells
on a plastic plate (Linbro Scientific Co., Hamden, CT, catalog
#FBl6-24TC).

Into each well was added 0.1 cc of the solution

being tested for LAF activity.

Into selected wells either

PHA (Phytohemagglutinin-P, Difco Laboratories; final concen¬
tration of 50 ug/cc), CON A (Concanavalin A, Calbiochem,
2.5 ug/cc) or 0.1 cc of the supernatant fraction from LPS~
stimulated cultured human peripheral blood leukocytes was
added.

The plates were incubated at 37°C with 5% CO2®

48 hours 1 uCi of tritiated thymidine

After

(1.9 uCi/mM; New England

Nuclear) in 0.1 cc of normal saline was added.
were then incubated for an additional 24 hours.

The plates
The contents

of the wells were harvested on a 24 sample manifold using
glass fiber gilter paper (Whatman, Inc., Clifton, NJ; catalog
#934AH) soaked in 1 mM thymidine.

The filter paper was then

washed with saline and 5% trichloroacetic acid and allowed to
air dry.

The filter paper discs were placed in vials

.

.

•-
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containing 2 cc of scintillation fluid (prepared from 3*8 1.
toluene, 19 gm 2, 5-diphenyloxazole, O.95O gm p-bis £2-(5 phenyloxazolyl benzene]] ) and counted for 1 minute in a liquid
scintillation counter.
All samples were assayed in triplicate, and the results
reported are the means + standard error.
Purification and Characterization of LAF
LAF was partially purified by eliminating certain
dialyzable inhibitory products®

Two to three cc of crude

LAF preparation was placed in a length of dialysis tubing and
allowed to stand overnight (12 to 18 hours) in 2 1. of pH ?»4
HEPES-saline solution (0.05 M HEPES + 0.9% saline).

The

non-dialyzable fraction was sterile filtered with a 45 u
Millipore filter prior to assay.
LAF was concentrated using an Amicon ultrafiltration unit
(Model 52) with a UM-10 membrane
daltons).

(nominal retention - 10,000

Forty cc. of crude splenic or peritoneal LAF was

concentrated to 10 cc®

These concentrates were used in the

molecular weight and isoelectric point determinations outlined
below®
Sephadex G-150 gel (Pharmacia) was prepared by boiling for
5 hours in 0.04 M HEPES-0.15 M sodium chloride buffer, pH ?®5®
The gel was poured into 25 x 0*5 cm columns and equilibrated
with the same buffer.

Columns were standardized with globulin,

albumin and cytochrome C.

The four-fold concentrated samples

(1.25 cc aliquots) were placed on top of the columns and eluted

*
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with the HEPES-chloride buffer.

One cc samples were collected

for assay.
Isoelectric focusing was performed on an LKB Model 8100
apparatus (Produkter, Sweden) with a 110 cc column containing
Ampholines with pH ranging from 3 to 10®

Eight cc of concen¬

trated LAF preparation was added to the column, and after 36
hours of focusing, 4 cc fractions were collected and the pH
of each sample was measured.

The samples were dialyzed

against two changes of the HEPES-chloride buffer and sterile
filtered prior to assay.

,

■

RESULTS
Production of LAF in the Peritoneum
Within the peritoneum, the response to intraperitoneally
injected lipopolysaccharide (LPS) is relatively rapid*
Analysis of the supernatant fraction of peritoneal washings
revealed a peak of mitogenic activity at 3 hours in the
absence of additional mitogens in the assay and at 6 hours
in the presence of either PHA or the supernatant fraction
from human peripheral blood leukocytes stimulated with LPS
(See Figure I)*
less by 24 hours*

Activity returned to base line values or
It is interesting to note that the addi¬

tion to the assay wells of cell-free peritoneal exudate from
mice receiving 0.2 cc of normal saline intraperitoneally
resulted in a decrease in the incorporation of tritiated
thymidine by the thymocytes*

This was also true for all

samples from LPS treated mice, except for the 3 and 6 hour
samples *
There was a definite relationship between the intraperitoneal dose of LPS and the mitogenic activity of the peri¬
toneal washings (See Figure II)*

Two out of three mice that

received 500 ug of LPS intraperitoneally died within 48 hours,
while no animals given normal saline or 100 ug of LPS died.
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3H-TdR Incorporation--CPM

6000

Time in Hours

FIGURE I--TIME COURSE OF LAF PRODUCTION IN THE SUPER¬
NATANT FRACTION OF PERITONEAL EXUDATE--B6D2FI mice received
50 jug of LPS intraperitoneally at Time = 0 and were sacrificed
after various Intervals*
The cell-free peritoneal exudate
was tested for its ability to enhance thymocyte mitogenesis
alone (O), in the presence of PHA (A), and in the presence of
the supernatant fraction of LPS-stimulated human peripheral
blood leukocytes (HUMAN SUP,D).
Control mice received
0*2 cc of normal saline intraperitoneally*
Cell free peri¬
toneal exudate from these mice was assayed alone (#), with
PHA (A) 1 and with HUMAN SUP (H).
Tritiated thymidine (3H-TdR)
incorporation was 617+88 for thymocytes without a mitogen,
888+20 for thymocytes and PHA and 20,745+1,423 for thymocytes
and HUMAN SUP.
All values are + standard error of the mean of
determinations.
3
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FIGURE II—RELATIONSHIP BETWEEN INTRAPERITONEAL LPS DOSE
AND LAF PRODUCTION IN THE CELL-FREE PERITONEAL EXUDATE—
Mice received various intraperitoneal doses of LPS suspended
in 0.2 cc of normal saline.
The animals were sacrificed
after 4 hours.
The supernatant fraction of the peritoneal
exudate was assayed alone (®), in the presence of PHA (a),
and in the presence of the supernatant fraction of LPSstimulated human peripheral blood leukocytes (HUMAN SUP,® ).
Tritiated thymidine (^H-TdR) incorporation was 1578+280 for
thymocytes without added mitogen, 1871+101 for thymocytes and
PHA, and 19,180+1,873 for thymocytes and HUMAN SUP.
All are mean
values are + standard error of 3 determinations.

/
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Mice given 100 ug of LPS were severely ill with diarrhea and
diminished activity.
Injection with the methanol extraction residue of BCG
(MEF.) also resulted in enhanced activity in the supernatant
fraction of the peritoneal washings.

Xntraperltoneal MER

Injection did not by itself result in increased supernatant
fraction activity after five days.

However,

a sub-optimal intraperitoneal dose of LPS

in mice given

(50 ug)

five days

after receiving 1 mg of MER there was a marked rise in
activity in the peritoneal washings four hours after the
LPS injection.

There was no detectable LAF activity in the

mice that had received an Injection of saline 5 days before
the LPS challange-(See Table I.).
Studies using radioactively labelled LPS revealed that
this substance is cleared rapidly from the peritoneum.

Four

hours after intraperitoneal injection only 0.15% of the
initial dose was recovered.

This can be compared to the

10.1% recovery Immediately following Injection.
addition of 0.1,

1,

10,

The

and 25 ug of LPS to the assay wells

in various experiments did not result in mitogenic activity
significantly different from that of the control.

Splenic LAF
Spleen cells from mice stimulated with LPS were capable
of releasing LAF when the cells were removed and cultured in
medium without serum.
for LAF production,

To determine the time response curve

spleens were excised at various intervals

after intraperitoneal injection of LPS and cultured in a 37°C

:

.
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TABLE I
ENHANCEMENT OF LPS INDUCED LAF PRODUCTION
BY TREATMENT WITH METHANOL EXTRACTION RESIDUE OF BCG (MER)

^H-TdR Incorporat ion

(CPM)

Treatment
Day 0

Day 5

Perit. Sup.
only

Perit. Sup
+PHA

Perit. Sup.
+Human Sup.

3511+244

7200+604

43634+3887

MER—Img

LPS-50ug

MER-lmg

Saline

2 ? 8+ 31

483+ 21

31043+1863

Saline

LPS-50ug

490+ 76

636+ 63

22155+1202

Saline

Saline

187+ 15

483+ 26

26392+ 572

708+280

1073+ 63
(FHA)

No Perit.

Sup.

Added

37372+2028
(Human Sup.)

Mice received either 1 mg of MER or 1 cc of normal
saline intraperitoneally on day 0 and 50 ug of LPS or 0.2 cc
of normal saline intraperitoneally on day 5*
Four hours
after the second injection the mice were sacrificed and a
supernatant fraction of the peritoneal exudate prepared.
All values reported are the mean of three determinations
4- standard error.

: i.
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incubator for a fixed

interval

(See Figure

III),

When all sam¬

ples were dialyzed against HEPES buffer prior to assay, a.
biphasic activity curve resulted.

There was a peak of production

at 3 hours and a secondary rise In activity at 24 hours.

(These

times are the interval between LPS injection and the removal
of the spleen from the animal®

They do not include the 6 hour

incubation period.)
The optimal incubation conditions were also determined®
(See Figure IV.)

The maximal rate of LAF release appeared to

occur during the l| hours between the injection of LPS and the
removal of the spleen from the mouse®

(Compare the values at

time 0 for the supernatant fractions from mice that had received
LPS and saline with values obtained from supernatant fractions
of spleen cells cultured for various lengths of time®

To obtain

time 0 values the spleen cell homogenate was centrifuged
ately and the supernatant promptly frozen.)

immedi¬

A peak of activity

occurred at 22 hours among the dialyzed samples®

The mitogenic

potential of the undialyzed samples was relatively constant®
At l'| and 4 hours the ratio of mitogenic activity of dialyzed
to undialyzed samples assayed in the presence of PHA or CON A
was 10-1*6.

However, at 22 hours this ratio was 2®3»

LAF

release was also a function of cell concentration in vitro®
higher cell concentrations

At

(2 x 10? cells/cc) less LAF activity

per spleen cell was produced

(See Table II).

Several unsuccessful attempts were made to stimulate LAF
release in splenocytes not exposed to LPS in vivo®

The

.
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FIGURE III—LAF PRODUCTION BY DIALYZED SUPERNATANT FRACTIONS
OF SPLEEN CELLS HARVESTED AT VARIOUS INTERVALS AFTER LPS
INJBCTI0N--Mice received 100 ug of LPS intraperitoneally
and were sacrificed at various intervals after the injection.
Spleen cells were incubated in MEM (without serum) for 6 hours
at a concentration of 3.5 x 10? cells/cc. The dialyzed supernatant
fractions of the cultures were assayed in the absence of
additional mitogens («), with PHA (A) or with CON A (■).
Spleen cells from mice given 0.2 cc of normal saline intra¬
peritoneally were harvested after li hours and cultured for
6 hours.
Initiated thymidine (3H-TdR) incorporation was
4551.26 for the supernatant fraction from these cells, 2?43+198
for this fraction and PHA and l4,556+3?4 for this fraction and
CON A.
Values for the control assay were 1225+224 for the
thymocytes withi^t any mitogens, 1192+352 for the thymocytes
and PHA, and 9850+1078 for the thymocytes and CON A.
All
values are the mean of three determinations + standard error.
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FIGURE IV--LAF PRODUCTION BY CULTURED SPLEEN CELLS EXPOSED
TO LPS IN VIVO--DIALYZED VS. UNDIALYZED SUPERNATANT
FRACTIONS--Mice received 100 ug LPS intraperitoneally
and were sacrificed l| hours later.
The spleens were homo¬
genized and 'cell concentration adjusted to 2 x 10^ cells/cc.
The
cells were incubated in MEM (without seum) for various lengths
of time.
Samples were dialyzed against HEPES and assayed in
the presence of PHA (A) or CON A (P).
Undialyzed samples were
also assayed with PHA (A) or CON A (®).
A group of mice
received 0.2 cc of normal saline instead of the LPS.
Super¬
natant fractions were prepared as described above and assayed
with PHA (SA) or CON A (SP).
Tritiated thymidine (3H-TdR)
incorporation was 1468+366 for the thymocytes without any mito¬
gen, 1198+255 for thymocytes and PHA, and 10,800+1121 for
thymocytes and CON A.
All values are the mean of three detrminations + standard error.
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TABLE II

EFFECT OF SPLEEN CELL CONCENTRATION
IN VITRO ON LAF PRODUCTION

Tritiated Thymidine Incorporation
Treatment
of mice

Spleen
cell cone ,

Spl. Sup
only

(CPM)

Spl. Sup.
Spl. Sup,
+PHA (50ug) +C0N A (2.5ug)

LPS-lOOug

5

X

105

806+10?

649+120

1923+189

LPS-lOOug

5

X

106

577+231

1812+288

4225+310

LPS-lOOug

2

X

10?

579+ 37

5541+181?

7555+391

Saline

5

X

lo5

629+ 30

752+ 93

1572+327

Saline

3

X

106

893+590

926+ 16

1423+6??

Saline

2

X

10?

398+ 73

660+ 4?

1005+327

No Spleen Sup,

.Added

689+262

936+164
(PHA only)

1649+154
(CON A only)

Mice received 100 ug of LPS or 0,2 cc of saline intraperitoneally and were sacrificed It hours later.
The spleens
were homogenized and the cell concentration was adjusted with
MEM (without serum).
Spleen cells were incubated for 6 hours,
and the supernatant fraction was obtained and assayed®
All
values reported are the mean of three determinations + stan¬
dard error.
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addition to unstimulated spleen cells of 2 ug/cc or 20 ug/cc
of LPS,

1 x 10? thymocytes,

0.05 cc/cc of human plasma or

various combinations of these agents failed to cause LAF
production.
Although the majority of the studies employed GDI thymo¬
cytes in the assay of LAF produced by B6D2F1 mice,

the allogenic

nature of the source of LAF and its assay target was not
essential for the demonstration of LAF activity.

LPS stimulated

spleen cells from GDI and C3H mice produced LAF activity
similar in magnitude
cytes (See Table III).
culture,

(+25%)

to that produced by B6D2F1 spleno-

GDI thymocytes were used in the assay

the dose of LPS was adjusted to the weight of the mouse

(3 ug LPS/gm mouse), and in vitro cell concentration and

incu¬

bation time were held constant.
The direct addition of GDI,

B6D2F1 or C3H spleen cells

exposed in vivo to LPS to the GDI thymocytes in the assay
wells resulted in total thymidine incorporation greater than
the algebraic sum of the thymidine incorporation by either
cell type alone

(See Table IV).

In the presence of CON A

the synergistic effect was also seen with unstimulated
splenocytes and thymocytes®
Tables II and III)

In other experiments

(See

the conditioned medium from unstimulated

splenocytes did not promote mitogenesis of thymocytes, and
in some cases it was slightly inhibitory.

Characterization of Murine LAF
Preliminary data obtained by G-150 Sephadex column
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TABLE III

PRODUCTION OF SPLEEN CELL LAF
IN DIFFERENT STRAINS OF MICE

Tritiated Thymidine Incorporation
Treatment
of mice

Strain
of mice

Spl. Sup.
only

Spl. Sup.
+PHA
(50 ug)

Spl. Sup.
+C0N A
(2.5 ug)

386+ ?8

1102+159

9767+663

LPS

(lOOug)

LPS

(lOOug)

GDI

6ll+ 13

1323+245

12058+471

LPS

(lOOug)

C3H

1096+322

917+114

7464+647

987+472

493+ 60

3478+213

Saline

B6D2F1

B6D2F1

(CPM)

Saline

GDI

486+189

890+208

3603+178

Saline

C3H

876+156

1092+230

3500+418

H66+333
(PHA only)

4779+686
(CON A only)

No Spleen Sup. Added

1130+277

Mice received 100 ug of LPS or 0,2 cc of saline IP and were
sacrificed l| hrs after the injection*
The spllen cells were
cultured for 5 hrs at a concentration of 1.2 x 10® cells/cc.
The undialyzed supernatant fractions were assayed.
All values
reported are the mean of three determinations + standard error*
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chromatography suggests that peritoneal LAF has a molecular
weight of 55*000 daltons (single determination of the ability
of various fractions from the column to enhance thymocyte
mitogenesis in the presence of CON A),

There was a secondary

peak of activity at 13,000 daltons (See Figure V •).
Splenic LAF appeared to have a molecular weight of
55*000 + 15*000 daltons (two determinations-- See Figure VI ,).
In one experiment there was a secondary peak of activity cor¬
responding to a molecular weight of 180,000,
The isoelectric point of splenic LAF was 5,0 + 0,1
determinations).

(two
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FIGURE _y--G-150 SEPHADEX COLUMN CHROMATOGRAPHY OF PERITONEAL LAF
Peritoneal LAF was prepared by injecting 100 ug of LPS
mtraperi.tonea.lly into B6D2F1 mice.
The mice were sacrificed
3 hrs after the injection and the peritoneums washed with 3.5
cc of MEM.
The supernatant fraction was obtained and concen¬
trated by a factor of 4.
An aliquot (1.25 cc) was placed on
^°P of a25 x 0.5 cm Sephadex G-150 column and eluted with
HEPES buffer.
Each 1.0 cc fraction was assayed with 2.5 ug of
CON A.
Initiated thymidine (3H-TdR) incorporation for the
thymocytes and CON A alone (X) was 42,308+9,667.
All values
are the mean of three determinations,
.

i
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FIGURE VI--G-150 SEPHADEX COLUMN CHROMATOGRAPHY OF SPLENIC LAF
Splenic LAF was prepared by Injecting 100 ug of LPS
intraperitoneally into B6D2F1 mice*
The mice were sacrificed
after lk hours and the spleens removed and homogenized*
The
spleen cells were incubated for 2 hours at 37°C, and the super¬
natant fraction was obtained and concentrated by a factor of
4,
An aliquot (1.25 cc) was placed on top of a 25 x 0.5 cm
Sephadex G-150 column and eluted with HEPES buffer.
Each 1.0
cc fraction was assayed with 2.5 ug of CON A and tritiated
thymidine (3H-TdR) incorporation by GDI thymocytes was measured.
All values represent the mean of three determinations.

I

DISCUSSION

These data confirmed the work of previous

investigators,

who demonstrated the production by leukocytes of a soluble
factor, which is capable of enhancing lymphocyte mitogenesis.
These experiments furthered this work by delineating an
in vivo system in which LPS rapidly produced LAF within the
peritoneum and spleen*

Peritoneal. LAF
The rapid accumulation of LAF within the peritoneum of
mice following the intraperitoneal injection of LPS is consistent with the results obtained by Yoshinaga e_t al.

They

demonstrated that cell free peritoneal exudate caused maximal
enhancement of thymocyte DNA synthesis when harvested 3 or 9
hours after the intraperitoneal injection of casein.
tunately,

Unfor¬

these cell-free peritoneal exudates were not

dialyzed.

If is possible that the release of thymidine by

inflammatory cells interfered with the assay, which measured
the incorporation of radioactively labelled thymidine by
thymocytes.

If a large amount of unlabelled

were present during the assay,

thymidine

the measured rate of DNA

synthesis would be decreased because of the dilution of the
radioactive precursor.

»
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The rapid production of LAF following challenge with an
inflammatory agent raises a question regarding the cellular
origin of LAF*

During the first 24 hours of inflammation the

predominant cell is the polymorphonuclear leukocyte.
after 3 days does the macrophage predominate.

1

u

Only

Yoshinaga et

ali^measured the direct enhancing effect of peritoneal exudate
cells on DNA synthesis by thymocytes stimulated with PHA
cell types plus PHA in the same well).
exudates

(both

They found that early

(93% polymorphonuclear leukocytes and 2% macrophages)

had a greater enhancing effect
hour exudate which contained

on DNA synthesis than the 96

73%

macrophages.

An earlier

report by Gery and Waksman J indicated that LAF was produced
almost entirely by the plastic-adherent cell population
(presumably macrophages).

These data suggest that other-

leukocytes can produce LAF,

although it is possible that, the

small number of macrophages present initially could have
produced a large quantity of LAF.
Very large doses of LPS

(50 jug per mouse or 2 ug/gm)

were required to cause the appearance of LAF activity in the
cell-free peritoneal exudate.

The 100 jag dose used

experiments caused the animals to become very
500 ug was a dose greater than the LD^q»

ill and

Some researchers

have demonstrated that very small doses of LPS
mouse)

in most

inhibit the growth of certain tumors®^*

(<1 ug per
'

Although it is possible that such small doses of LPS had a
slight effect on LAF production,
current assay methods*

this was undetectable by

-

.
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The intraperitoneal injection of MER 5 days before the
LPS challenge resulted in greatly increased LAF production
within the peritoneum.

However, MER alone did not produce an

increase in LAF production.

The peritoneum in the normal

mouse contains few macrophages or polymorphonuclear leuko¬
cytes , but during inflammation the number of cells increases®
The chronic inflammation may also enhance the ability of LPS
to release LAF by stimulating the formation and storage of
LAF.

It can be hypothesized that the injection of LPS into

the already inflamed peritoneum provokes the rapid release of
LAF* which has been manufactured in response to MER.
contrast, Gery et al.

20

In

have demonstrated that peritoneal-

exudate cells will release more LAF in culture when they are
removed from a mouse that has been treated with MER than when
they are derived from an unstimulated animal, and that no
further stimulation is required®
Splenic LAF
Rapid production of LAF also occurred in splenocytes®
Within 3 hours (!§- hours between injection and the start of
incubation and l| hours of incubation with medium) signifi¬
cant activity was already present®

The earliest activity

noted by Blyden and Handschumacher^-® in the conditioned
medium from in vitro stimulated human peripheral blood
leukocytes occurred after 6 hours.

The processing of LPS

and stimulation of LAF production appear to be faster when
the LPS is presented to the cells in an in vivo system.

Previous reports from this laboratory1® have suggested
that LAF is produced by leukocytes and not merely released*
When unstimulated leukocytes were lysed osmotically and the
supernatant fraction cultured with LPS for 24 hours, the
activity was less than 10% that of intact leukocytes®

This

also suggests that the activity is not simply a degradation
product of LPS* but it does not rule out the possiblity
that LAF is the product of a larger precursor molecule*
whose enzymatic breakdown is stimulated by LPS®
The biphasic production of LAF could be interpreted in
several ways®

There could be a precursor molecule available

for rapid conversion or there could be rapid peptide syntesis®
The secondary peak seen at 24 hours may reflect adaptation by
the cell via enhanced protein

synthesis®

It is also possible

that different cell types (polymorphonuclear leukocytes and
macrophages) produce LAF at different times®

In interpreting

these data caution must be employed, since the amount of LAF
activity represents

the algebraic sum of the production and

breakdown of LAF in the system®

The lower value at 9 hours

could simply be the result of the breakdown of the large
amount of LAF produced within the first 2 hours®
The ability of unstimulated splenocytes to enhance
mitogenesis in thymocytes when the two cell populations
are cultured together with CON A suggests that some type of
cellular cooperation (enhancement of LAF production by a
thymocyte product or direct cellular contact) may be

.#‘01. t
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involved.

Conditioned medium from unstimulated splenocytes

did not promote mitogenesis of thymocytes, and in some cases
it was slightly inhibitory®

Gery and Waksman1^ and Mokyr and

Mitchell0^ postulated that CON A stimulates the thymocyte,
which causes the splenocyte to produce LAF, which in turn fur¬
ther enhances thymocyte DNA synthesis.

It would be worthwhile

to perform a diffusion chamber experiment to determine if solu¬
ble factors were responsible for this synergistic phenomenon
or whether direct cellular contact was required.
The LAF assay as developed by Gery,

Gershon and Waksman

11

18
and modified by Blyden and Handschumacher1
was employed
throughout this study.

During the two years

in which these

studies were performed,

there was considerable variation in

the absolute number of counts of radioactive thymidine
incorporated by the thymocytes.

This occurred despite the

fact that the reagents were not changed

(all serum came

from the same lot) and the mice were obtained from the same
source.

Gross bacterial contamination was quite obvious when

it occurred and was a problem in only a few experiments.
Inspection of the actual values obtained for cell-free peri¬
toneal exudate and for splenocyte LAF reveals a substantial
difference in the absolute amount of thymidine incorporation.
Values for a standard mitogen (CON A) and supernatant frac¬
tions prepared from human peripheral blood leukocytes were
substantially lower than the values seen at other times in
this and other laboratories.

The human leukocyte supernatant

12
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fraction yielded ~20,000 CPM in the peritoneal exudate stu¬
dies and only^2»G0Q in the splenocyte experiments

(compared

to values of ^1,000 for thymocytes cultured without any
stimulants)®

It should be noted that these two sets of

experiments were performed 12 months apart*
of the assay was reevaluated,
the discrepancy.*

Each component

but no reason was found for

It Is possible that a subeXinical viral

infection could have resulted in a loss of immunocompetence.
For example,

it has been shown that human measles vaccination^!

and Epstein-Barr viral infection^
can result in decreased

(infectious mononucleosis)

immunocompetence,

as measured by

anergy to the Mantoux tuberculin and Candida Intradermal
tests and the response of lymphocytes to PHA,

pokeweed mitogen

and allogeneic lymphocytes.
Since the supernatant fraction of cultured GDI splenocytes caused mitogenesis of GDI thymocytes,

the role of

strain differences as the sole cause of this phenomenon
can be excluded.

B6D2F1

thymocytes did not respond as well

as those from the GDI mice, and

it is for this reason that

GDI thymocytes were used in the assay.
The effect of dialysis on the supernatant fractions
assayed can be demonstrated by comparing the LAF activity of
the dialyzed and undialyzed samples from splenocytes incubated
with medium for various time intervals.
difference

The increasing

in LAF activity between dialyzed and undialyzed

samples could be explained by the production of increasing

•»

«

a
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quantities of a dialyzable inhibitor that obscures the eleva¬
tion of LAF.
suppressor.

Indeed Opitz and his group^0 studied a similar
They found that it merely reduced the incor¬

poration of tritiated thymidine*
proliferation.

but did not inhibit cell

The factor was heat stable and dialyzable

and apparently was a cellular degradation product,

since it

was produced when T-lymphocytes and macrophages were culti¬
vated together,

but not when they were cultured in opposite

sides of a diffusion chamber.

This was consistent with the

inhibitor being thymidine, which could interfere with
tritiated thymidine uptake by increasing the ratio of cold
thymidine to radioactive thymidine in the assay wells.

Characterization and Purification of LAF
Preliminary data indicates that the molecular weight of
murine LAF (55*000 daltons)

is much greater than that of the

LAF obtained from human peripheral blood leukocytes
daltons)10*

(13*000

and values previously reported for murine LAF

(5*000-25*000 daltons^

The value obtained in these

experiments appears to be similar to the molecular weight of
the LAF from the murine cell line,

P388-DI

(80,000 dal tons

The isoelectric point (pi) of the murine splenic LAF (5*0)
is similar to that of the murine cell line LAF (pi = 4.8-5*0).35
18
The pi of the human leukocyte LAF is 6.8-7 • 0. “
The molecular weight values were obtained with a rela¬
tively small column (25 x 0.5 cm) and each 1 cc fraction
differed in molecular weight by 10,000 daltons in the range

,
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of the peak values®

Molecular weight determination with

larger columns would be useful®

The apparent molecular

weight of the splenic LAF was only approximately twice the
magnitude of the baseline activity,;, and the significance
of the secondary peak
not be determined®

at 180,000 daltons in one run can

These molecular weights represent

peaks of activity in the presence of the mitogen,

CON A.

The fractions in the absence of mitogens failed to enhance
DNA synthesis®

Since CON A stimulates immature thymocytes,

the molecule which enhances the CON A response may be different
from that which affects another portion of the thymocyte
population®

It is conceivable that the fractions assayed

in

the absence of a mitogen would have produced a peak of acti¬
vity corresponding to a different molecular weight®

However,

the fractions of human LAF which maximally enhanced CON A
induced mitogenesis had the same molecular weight as those
which enhanced thymocyte mitogenesis in the presence of PHA
and in the absence of any mitogen®

The murine LAF was

obtained 4 to 6 hours after the animals were injected with
LPS, and it is possible that LAF with a different molecular
weight could appear later®

Implications for Immunotherapy
This research demonstrates that an intraperitoneal
endotoxin challenge to a living animal can lead to the rapid
production of LAF by cells in the peritoneum and spleen.
The LPS resulted in considerable toxicity, and

it would be

*
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worthwhile to determine if a derivative of this complex
material could produce the same LAF response with less toxicity*
Different routes of endotoxin administration (intravenous or
subcutaneous) might also be considered.
The experiments performed measured the amount of LAF in
the immediate proximity of the cells producing this substance®
It would be valuable to measure the concentration of this
substance in the blood stream of mice receiving intraperitoneal LPS.
One of the distant objectives of these studies is to
purify LAF and determine if non-specific stimulation of the
immune system of cancer patients could effect the course of
their disease.

The apparent differences between human and

murine LAF indicate the need for caution in applying the
results from one species to another.
experiments

In preliminary

(data not included), very crude preparations of

human and murine LAF were unable to inhibit the growth of
L1210 leukemia in B6B2F1 mice.

Better preparations of LAF

and different dosage schedules may prove more successful,
and other tumors may be more responsive than LI210.
Another possible use of LAF is in the treatment of
congenital immunodeficiency disease.

Although LAF by itself

will not replace the many components of the immune system,
it might prove valuable as an adjuvant in treating certain
diseases.

Two diseases in which cell-mediated immunity is

deficient, mucocutaneous candidiasis and the Wiskott-Aldrich

4?
syndrome (eczema, thrombocytopenia and immunodeficiency),
have responded in some cases to another substance, transfer
factor*

-)f

This substance is a dialyzable extract of

sensitized leukocytes which transfers reactivity from skin
test positive donors to skin test negative recipients®

6?

is possible that the use of LAF might cause these patients
to respond immunologically to a wider variety of antigens.

It
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